USA Rare Earth Stock Falls 41% From Peak as Production Timeline Extends

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

USA Rare Earth stock plunged 41% from October peak as production timelines extend, with magnet factory opening delayed to mid-2026 and mining production pushed to 2028.

USA Rare Earth Stock Falls 41% From Peak as Production Timeline Extends

USA Rare Earth's stock has declined substantially from its October 2025 high of $32 per share to below $19, erasing nearly 41% of its value as investors reassess the company's path to profitability. The decline reflects growing concerns about the extended timeline to revenue generation, despite significant government backing and strategic importance to U.S. supply chain resilience.

The company is advancing an ambitious dual-facility development strategy supported by $1.6 billion in funding from the Trump administration. USA Rare Earth plans to commence operations at its Oklahoma magnet factory in the first half of 2026, followed by rare-earth mine production in 2028. These facilities are designed to reduce U.S. dependence on Chinese permanent magnets, a critical component for defense, renewable energy, and advanced manufacturing applications.

While federal funding and geopolitical tailwinds provide structural support for the company's long-term prospects, investors are grappling with the reality that substantial revenue generation remains several years away. The stock decline suggests the market may be pricing in execution risks and the extended capital-intensive development phase ahead. Industry observers will likely monitor the company's progress on the magnet factory opening and its ability to meet production timelines as key catalysts for investor sentiment in 2026.

Source: The Motley Fool

Back to newsPublished Feb 25

Related Coverage

The Motley Fool

Rivian's $1.25B Uber Deal: Lifeline or Distraction From Profitability?

Uber invests $1.25B in Rivian, orders 50,000 autonomous R2 vehicles by 2031. Rivian delays profitability target to fund robotaxi development.

GOOGGOOGLUBER
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR